Our Story

Jonathan Tobin

Partner - London

Jonathan joined Brandon Capital in 2021.

Jonathan is a Partner in Brandon’s London office and serves on the boards of Brandon portfolio companies Pheon, Myricx Pharma, NRG Therapeutics, and Catalym.

Prior to joining Brandon, Jonathan was a Managing Director at Arix Bioscience, a UK and US-based biotech venture firm, where he helped build the team and portfolio, and sat on the boards of a number of companies including: Artios Pharma, Atox Bio, Depixus, STipe Therapeutics, and VelosBio (acquired by Merck in 2020 for $2.75bn), as well as sourcing investments in Gensight (Euronext: SIGHT), TwelveBio (acquired by Ensoma), and Pyxis Oncology (NASDAQ: PYXS).

Prior to Arix, Jonathan spent five years at UK early-stage venture capital firm Touchstone Innovations, where he was a Principal in the Healthcare Ventures team and helped create and build several university spin-outs, including liquid biopsy company Inivata (acquired by Neogenomics for $415m in 2021). He also worked at LifeArc, sourcing and evaluating new small molecule and antibody drug discovery projects.

Jonathan has a first-class degree in Biology from the University of Oxford; a PhD in Molecular Medicine from University College London (UCL) focusing on rare genetic diseases; carried out postdoctoral research on cancer cell signalling at the Cancer Research UK London Research Institute (now Crick Institute), and published research in top-tier journals including Nature Genetics, PNAS, and the New England Journal of Medicine. Jonathan has an MBA with Distinction specialising in Investment & Risk from Imperial College London. He serves as a trustee on the board of the Autism Centre for Excellence in Cambridge, and is a member of the Investment Advisory Committee of the KHAN drug discovery fund in Germany.

Brandon Capital is aware of scammers impersonating us - offering jobs and asking for bank details. We do not offer employment or ask for banking details via SMS, websites or phone calls. Do not provide any details and report to the relevant authorities in your location.